OTTAWA, July 23 /CNW Telbec/ - Chemaphor Inc. (TSXV: CFR) today announced
pursuant to the requirements of the TSX Venture Exchange, that on July 8, 2008
it granted options to purchase 525,000 common shares of Chemaphor to directors
and officers. The stock options were granted pursuant to the terms of
Chemaphor's stock option plan and are exercisable at $0.20 per share (based on
the July 7th closing price). These grants form part of a total remuneration
package. Stock option grants are subject to necessary regulatory approvals.
About Chemaphor Inc.
Chemaphor Inc. (www.chemaphor.com) uses its core expertise in organic
chemistry to develop premium products for the animal health, skin care
cosmetics, pharmaceutical and specialty chemical markets. The Company's focus
is on two proprietary products, a non pharmaceutical product OxBC and a lead
cancer drug compound OCL-1. Chemaphor's goal is to fully exploit its
proprietary platform of carotenoid oxidation compounds by finding recognized
partners to commercialize its products in multiple, large markets.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Investor Relations, Groupe Evolution Inc.,
Sylvain Archambault, (514) 448-4887; Toll free: (866) 703-4887,